The European Union has reached a provisional agreement on the Critical Medicines Act, a landmark initiative designed to bolster the supply of essential medicines and prevent future shortages.
The deal focuses on strengthening domestic production of critical medicines—such as antibiotics, insulin, vaccines, and painkillers—while reducing reliance on imports. This move addresses vulnerabilities exposed during the Covid-19 pandemic, particularly for over 200 medicines deemed vital to the region’s health security, including treatments for rare diseases.
Key Objectives of the Critical Medicines Act
- Enhance the supply of essential medicines to avoid shortages.
- Boost domestic production and reduce dependence on foreign imports.
- Strengthen supply-chain resilience for over 200 critical drugs.
- Include treatments for rare diseases to ensure comprehensive health security.
Statement from EU Health Officials
Neophytos Charalambides, Cyprus’s health minister, emphasized the significance of the agreement in a statement:
“With today’s agreement, we are taking practical action to reduce our vulnerabilities, diversify supply chains and strengthen Europe’s capacity to produce critical medicines and their ingredients closer to home.”